Bradykinin

Bradykinin (CPC catalog code BRAK-001) is a synthetic cardiovascular research peptide in the cardiovascular category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Bradykinin as a reference standard in cardiovascular workflows — for example, vascular reactivity in aortic ring and mesenteric bed preparations and renin–angiotensin–aldosterone system (raas) mechanistic studies. Human clinical evidence is not established.

No. Bradykinin is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a cardiovascular workflow, Bradykinin is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand-binding, IP-1 / cAMP HTRF, and organ-bath tension recordings are the standard readouts.

Stable lyophilized at −20 °C for ≥24 months. Reconstitute in normal saline or PBS. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for BRAK-001. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.